▲ 1.28%
prev close
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Congressional Trades
10
All tracked trades
Members Trading
7
Unique members
Net Activity
+2
6 buys · 4 sells
Members Who Traded This Stock
10 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-09-23 | GILDGilead Sciences Inc | Sell | $1,001 - $15,000 | 285d ago | — | |
| 2025-05-05 | GILDGilead Sciences Inc | Buy | $1,001 - $15,000 | 442d ago | — | |
| 2025-04-16 | GILDGilead Sciences Inc | Sell | $1,001 - $15,000 | 434d ago | — | |
| 2025-03-10 | GILDGilead Sciences Inc | Buy | $1,001 - $15,000 | 467d ago | — | |
| 2025-03-07 | GILDGilead Sciences Inc | Buy | $1,001 - $15,000 | 468d ago | — | |
| 2024-10-29 | GILDGilead Sciences Inc | Buy | $1,001 - $15,000 | 313d ago | — | |
| 2023-09-26 | GILDGilead Sciences Inc | Buy | $1,001 - $15,000 | 986d ago | — | |
| 2023-07-12 | GILDGilead Sciences Inc | Sell | $15,001 - $50,000 | 1074d ago | — | |
| 2023-03-06 | GILDGilead Sciences Inc | Buy | $15,001 - $50,000 | 1192d ago | — | |
| 2021-11-10 | GILDGilead Sciences Inc | Sell | $15,001 - $50,000 | 1419d ago | — |
2025-09-23
Valerie Hoyle
GILD
Amount
$1,001 - $15,000
Filed
285d ago
2025-05-05
Marjorie Taylor Greene
GILD
Amount
$1,001 - $15,000
Filed
442d ago
2025-04-16
John Boozman
GILD
Amount
$1,001 - $15,000
Filed
434d ago
2025-03-10
Carol Devine Miller
GILD
Amount
$1,001 - $15,000
Filed
467d ago
2025-03-07
Josh Gottheimer
GILD
Amount
$1,001 - $15,000
Filed
468d ago
2024-10-29
Valerie Hoyle
GILD
Amount
$1,001 - $15,000
Filed
313d ago
2023-09-26
Greg Stanton
GILD
Amount
$1,001 - $15,000
Filed
986d ago
2023-07-12
Daniel Goldman
GILD
Amount
$15,001 - $50,000
Filed
1074d ago
2023-03-06
Daniel Goldman
GILD
Amount
$15,001 - $50,000
Filed
1192d ago
2021-11-10
Carol Devine Miller
GILD
Amount
$15,001 - $50,000
Filed
1419d ago
Recent News
Powered by Polygon.io
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating
Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider
Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance?
Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.
Trade Timeline
Congressional activity, newest first
Valerie Hoyle
2025-09-23 · Sale
$1,001 - $15,000
Marjorie Taylor Greene
2025-05-05 · Purchase
$1,001 - $15,000
John Boozman
2025-04-16 · Sale
$1,001 - $15,000
Carol Devine Miller
2025-03-10 · Purchase
$1,001 - $15,000
Josh Gottheimer
2025-03-07 · Purchase
$1,001 - $15,000
Valerie Hoyle
2024-10-29 · Purchase
$1,001 - $15,000
Greg Stanton
2023-09-26 · Purchase
$1,001 - $15,000
Daniel Goldman
2023-07-12 · Sale
$15,001 - $50,000
Daniel Goldman
2023-03-06 · Purchase
$15,001 - $50,000
Carol Devine Miller
2021-11-10 · Sale
$15,001 - $50,000